Wiki · IBD-U
41 questions, drawn from this site's literature corpus. Draft pages are not yet clinician-reviewed.
What is the annual incidence rate of CRC in patients with UC lasting more than ten years draftDoes chromoendoscopy improve dysplasia detection rates compared to standard white-light colonoscopy in UC draftWhere does evidence conflict on the benefit of chromoendoscopy versus white-light endoscopy for detecting dysplasia in UC draftWhat is the 30-day postoperative complication rate after subtotal colectomy for patients with IBDU draftIs the rate of progression to CD higher in patients with indeterminate colitis than in those with IBDU draftIn newly diagnosed IBDU with pancolitis and no small bowel involvement, is mesalamine or biologic therapy preferred draftIn adults with indeterminate colitis and persistent symptoms despite optimized mesalamine, is colectomy or anti-TNF therapy preferred draftWhat is the evidence for fecal calprotectin thresholds to distinguish indeterminate colitis from CD, and how reliable are these cutoffs across laboratories draftIn adults with newly diagnosed IBD, what proportion are reclassified from UC to CD within two years of follow-up draftIn adults with suspected UC and ambiguous endoscopic findings, is MRE or capsule endoscopy preferred to clarify the diagnosis before biologic therapy draftWhat evidence challenges the stability of IBD subtype classification over 10 years, and are there conflicting reported reclassification rates between CD and UC draftIn ileocolic resection for suspected CD, should the pathology report include assessment of skip lesions and transmural inflammation severity to guide postoperative therapy draftWhat is the evidence that noncaseating granulomas in a colectomy specimen reliably distinguish CD from UC, given conflicting reports on their specificity draftWhat is the diagnostic yield of capsule endoscopy for detecting small bowel CD lesions in adults draftDoes MRE detect small bowel CD activity more accurately than CT enterography draftWhy is the evidence on capsule endoscopy sensitivity for detecting submucosal small bowel lesions inconsistent across studies draftDoes IPAA result in higher postoperative complication rates compared to total colectomy alone in patients with IBDU draftIn IBDU with a history of severe colitis but preserved rectum, is restorative proctocolectomy with IPAA or subtotal colectomy with ileostomy preferred draftWhat is the evidence for IPAA over total colectomy in indeterminate colitis, given conflicting reports on long-term functional outcomes draftWhat is the evidence on the long-term safety profile of anti-TNF agents in patients with indeterminate colitis compared to those with CD draftDoes stapled ileoanal anastomosis increase the risk of de novo CD compared with hand-sewn anastomosis after IPAA for UC draftWhat is the definition of pouch failure used in most clinical studies evaluating IPAA outcomes draftWhat is the evidence that patients with IBD of uncertain type have a higher rate of pouch failure after restorative proctocolectomy, and are there conflicting data draftDoes combined ASCA and pANCA testing yield higher diagnostic accuracy than either marker alone for distinguishing CD from UC draftGiven inconsistent ASCA performance across ethnic groups, how reliably does ASCA positivity indicate CD in a diverse patient population draftHow is IBDU defined and how does it differ from indeterminate colitis draftWhat proportion of patients with IBDU are eventually reclassified as CD or UC draftDoes a diagnosis of IBDU affect pouchitis risk after IPAA draftWhat is the role of histopathology in diagnosing indeterminate colitis at colectomy draftIn patients with indeterminate colitis, does anti-TNF therapy result in similar clinical remission rates compared with standard medical therapy (e.g., immunomodulators, steroids) draftWhat is the accuracy of the Padua Prognostic Score for predicting postoperative CD in patients undergoing restorative proctocolectomy draftIn patients with UC undergoing restorative proctocolectomy with IPAA, does preoperative anti-TNF therapy reduce the risk of postoperative pouch failure compared with surgery alone draftIn pediatric IBD, what are the key differences between CD and UC in treatment approaches or diagnostic changes draftIn patients with IBD who develop Clostridium difficile infection, how does escalating corticosteroid therapy compare with modifying biologic or immunomodulator regimens for the likelihood of colon surgery and other adverse outcomes draftIn indeterminate colitis diagnosed by endoscopy and biopsy, does anti-TNF therapy lead to a higher rate of sustained clinical remission at one year than immunomodulators (azathioprine or 6-MP) draftIn patients initially diagnosed with indeterminate colitis, what is the diagnostic accuracy of the DEFA5 bioassay versus standard histological methods (IHC) for differentiating Crohn's colitis from UC draftAs rescue therapy for steroid-refractory severe UC, is infliximab or ciclosporin preferred to reduce long-term colectomy rates draftWhat is the evidence for mycophenolate mofetil in patients with IBD refractory to conventional medical therapy draftIn children with suspected IBD, what is the evidence for ASCA and p-ANCA testing to differentiate UC from CD draftWhat histological features are most specific for diagnosing CD in fulminant colitis specimens draftWhat proportion of children diagnosed with indeterminate colitis were reclassified as UC or CD during follow-up draft